文献速递腹部技术与安全CT

MDCT上3级胰腺神经内分泌肿瘤:建立诊断模型并与胰腺导管腺癌比较生存

Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · AJR Am J Roentgenol · 2020-05-20

回顾性纳入经手术或活检证实的20例G3胰腺神经内分泌肿瘤(PNET)与58例胰腺导管腺癌(PDAC)患者,建立鉴别两者的诊断模型。多因素分析显示CA 19-9正常、肿瘤呈圆形、胰管扩张≤4 mm为G3 PNET独立预测因素,模型AUC 0.916,敏感度90.0%、特异度81.0%。G3 PNET患者总生存优于PDAC患者,且G3 PNET亚组中有肝或淋巴结转移者总生存差于无转移者。

要点

  • CA 19-9正常、肿瘤呈圆形、胰管扩张≤4 mm为G3 PNET的独立预测因素。
  • 诊断模型鉴别G3 PNET与PDAC的AUC为0.916,敏感度90.0%、特异度81.0%。
  • G3 PNET患者总生存优于PDAC患者;G3 PNET中伴肝或淋巴结转移者总生存更差。

关键影像表现/征象

  • G3 PNET较PDAC更常表现为CA 19-9水平正常、胰管正常、肿瘤呈圆形且边界清晰。
  • G3 PNET的门静脉期强化率高于PDAC(p < 0.05)。

诊断标准与关键数值

  • CA 19-9正常鉴别G3 PNET的OR为0.0125(95% CI 0.0008-0.2036)。
  • 肿瘤呈圆形鉴别G3 PNET的OR为0.0143(95% CI 0.0004-0.5461)。
  • 胰管扩张≤4 mm鉴别G3 PNET的OR为17.9804(95% CI 1.0098-320.1711)。
  • 诊断模型ROC曲线AUC为0.916,敏感度90.0%、特异度81.0%。

临床应用与阅片要点

  • 阅片时关注CA 19-9是否正常、肿瘤形态是否呈圆形、胰管扩张是否≤4 mm,以辅助鉴别G3 PNET与PDAC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study is to establish a diagnostic model for differentiating grade 3 (G3) pancreatic neuroendocrine tumors (PNETs) from pancreatic ductal adenocarcinomas (PDACs) and to analyze survival outcomes. MATERIALS AND METHODS. Twenty patients with G3 PNETs and 58 patients with PDACs confirmed by surgery or biopsy were retrospectively included. Demographic and radiologic information was collected. Univariate analyses and binary logistic regression analyses were performed to identify independent factors and establish a diagnostic model. An ROC curve was created to determine diagnostic ability. Kaplan-Meier survival analysis was performed. RESULTS. Patients with G3 PNETs were more likely to present with normal carbohydrate antigen (CA) 19-9 levels, normal pancreatic ducts, and round tumors with well-defined margins and higher portal enhancement ratios than were patients with PDAC (p < 0.05). After multivariate analysis, a normal CA 19-9 level (odds ratio, 0.0125; 95% CI, 0.0008-0.2036), round tumor shape (odds ratio, 0.0143; 95% CI, 0.0004-0.5461), and pancreatic duct dilation of 4 mm or less (odds ratio, 17.9804; 95% CI, 1.0098-320.1711) were independent predictors of G3 PNETs. The AUC of the ROC curve was 0.916, and sensitivity and specificity were 90.0% and 81.0%, respectively. Furthermore, patients with G3 PNETs had better overall survival than patients with PDACs. Among patients in the G3 PNET subgroup, patients with liver or lymph node metastases had worse overall survival than patients without metastases. CONCLUSION. A diagnostic model was established to differentiate G3 PNETs from PDACs. A normal CA 19-9 level, round tumor shape, and pancreatic duct dilation of 4 mm or less were factors that were strongly predictive of G3 PNET.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Chen HY, Zhang XY, Deng XY, et al. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020. PMID: 32432906. doi:10.2214/AJR.19.21921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。